Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]- cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignancies

European Journal of Clinical Pharmacology

Volumn 52, Issue 3, 1997, Pages 199-203

  Martinsson, P ^a   Nygren, P ^a   Fridborg, H ^a   Nilsson, K ^a   Kristensen, J ^a   Larsson, R ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cyclosporins; cytotoxicity; Haematological tumours; Human tumour cells

Indexed keywords

CYCLOSPORIN A; CYTARABINE; MELPHALAN; VALSPODAR; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DOSE RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CYCLOSPORINE; CYCLOSPORINS; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOLOGIC NEOPLASMS; HUMANS; TUMOR CELLS, CULTURED;

EID: 0030962242     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050274     Document Type: Article

References (24)

1. Bergui L, Gregoretti M, Caligaris-Calippo F (1994) Cyclosporin A in the treatment of B-chronic lymphocytic leukemia (B-CLL). Leukemia 8: 1245-1246
2. Botling J, Liminga G, Larsson R, Nygren P, Nilsson K (1994) Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human D-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer 58: 269-214
3. Cheng A, Su I, Chen Y, Lee T, Wang C (1993) Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 11: 109-115
4. Chikkappa G, Pasquale D, Phillips P, Mangan K, Tsan M (1987) Cyclosporin-A for the treatment of pure red cell aplasia in a patient with chronic lymphocytic leukemia. Am J Hematol 26: 179-189
5. Christen R, Morant R, Fehr J (1989) Cyclosporin-A therapy of pure red aplasia in a patient with B-cell chronic lymphocytic leukemia. Eur J Haematol 42: 303-307
6. Cumber P, Jacobs A, Hoy T, Fisher J, Whittaker J, Tsurou T (1990) Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukaemia. Br J Haematol 76: 226-230
7. DeVita V (1989) Principles of chemotherapy. In: DeVita V, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology. JB Lippincott, Philadelphia, pp 276-395
8. Emilia G, Messora C, Bensi L (1995) The use of Cyclosporin-A in the treatment of B-chronic lymphocytic leukemia. Leukemia 9: 357-361
9. Friesen C, Herr I, Krammer PH, Debatin K (1996) Involvement of the CD95 (APO-1 Fas) receptor ligand system in drug-induced apoptosis in leukemia cells. Nature Medicine 2: 574-577
10. Gaveriaux C, Boesch D, Jachez B, Bollinger B, Payne T, Loor F (1991) SDZ PSC 833, a noti-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 2: 225-234
11. Goldstein L, Galski H, Fojo A, Willingham M, Lai S, Gazdar A, Pirker R, Green A, Crist W, Brodeur G, Lieber M, Cossman J, Gottesman M, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Ca Inst 81: 116-124
12. Hannam-Harris A, Taylor D, Norwell P (1985) Cyclosporin A directly inhibits human B cell proliferation by more than a single mechanism. Leukoc Biol 38: 231-239
13. Larsson R, Nygren P (1990) Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. Int J Cancer 46: 67-72
14. Larsson R, Csoka K, Kristensen J, Nilsson K, Nygren P (1992a) Selective cytotoxic activity of cyclosporins against tumor cells from patients with chronic lymphocytic leukemia. Eur J Pharmacol. 53: 23-30
15. Larsson R, Kristensen J, Sandberg C, Nygren P (1992b) Laboratory determination of chemotherapetitic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177-185
16. List A, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W (1993) Phase I II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660
17. Marie J, Bastie J, Coloma F, Faussat Suberville A, Delmer A, Rio B, Delmas-Marsalet B, Leroux G, Casassus P, Baumelou E, Catalin J, Zittoun R (1993) Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 7: 821-824
18. Nygren P, Larsson R (1991) Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int J Cancer 48: 598-604
19. Nygren P, Kristensen J, Sundström C, Lönnerholm G, Kreuger A, Larsson R (1992) Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 6: 1121-1128
20. Nygren P, Fridborg H, Csoka K, Sundström C, de la Torre M, Kristensen J, Bergh J, Hagberg H, Glimelius B, Rastad J, Tholander B, Larsson R (1994) Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 56: 715-720
21. Tötterman T, Danersund K, Nilsson K, Killander A (1982) Cyclosporin A is selectively cytotoxic to human leukemic T cells in vitro. Blood 59: 1103
22. Twentyman P (1988) A possible role for cyclosporins in cancer chemotherapy. Anticancer Res 8: 985-994
23. Van Den Neste E, Maerevoet M, Martiat P, Ferrant A, Delannoy A, Michaux J (1995) Cyclosporin A in the treatment of refractory B chronic lymphocytic leukemia (B-CLL). Leukemia 9: 1102-1103
24. Zwitter M (1988) On the potential role of cyclosporin in the treatment of lymphoproliferative diseases. Leuk Res 12: 243-248